



Yale School of Medicine

Autism Genetics

*Matthew W. State, MD, PhD
Donald J. Cohen Associate Professor
Of Child Psychiatry, Psychiatry and Genetics
Deputy Chairman for Research,
Department of Psychiatry
Yale University School of Medicine
New Haven CT,
Matthew.State @yale.edu*

2. Outline



- Why genetics?
 - Why has it been so hard to find genes involved in ASD?
 - What does the recent data show?
 - What's next?
-

3. Why Genetics?



- Genetics as an entre into biology:
 - An understanding of molecular and cellular mechanisms promises to dramatically improve the opportunities to intervene in a rational way
 - Multiple concrete examples in common medical conditions: Alzheimer, hypercholesterolemia, cancer, hypertension
 - Fragile X, Tuberous Sclerosis, Neurofibromatosis
 - Identifying population risks
 - Clinical diagnoses
 - Study natural history and response to treatment
 - Helps clarify the role of the environment
-

4. The Heritability of ASD



- Heritability is the proportion of the variance of a phenotype/disorder explained by genetic variation
- Heritability is not inheritance. Disorder may have a genetic component without being inherited: new (*de novo*) mutation
- 8 studies since 1977 evaluated twins and ASD diagnosis
 - Prior heritability estimates 0.73-0.93
 - Hallmayer et al (*Arch Gen Psych* 2011) show the lowest overall heritability (~ 0.4 ; 95% CI 0.08 - 0.84)

5. The Heritability of ASD



- Every study has strengths and weaknesses:
 - Careful clinical assessment, large sample (202 pairs)
 - very low response rate (202/1156 total twins) which can influence estimates of dizygotic concordance
 - Large for a twin study, but small numbers for some analyses (<10 MZ female pairs)
 - Slightly higher concordance for identical twins, much higher concordance of non-identical twins (vs. Bailey et al, *Psychol Med* 1995)
- Adds to a body of knowledge; does not supplant it

6. Heritability



- If these estimates are replicated, it still does not tell us that we should study one and not the other
 - Genes vs. environment is a false dichotomy
 - Hard to think of a common medical condition that does not involve the interplay of environment and genetic risks
 - The heritability of high blood pressure is $\sim 0.3-0.5$; the heritability of breast cancer is ~ 0.3 ;
 - Genetic studies in these and other conditions have led to critical insights into biology leading to new treatments, improved diagnosis and prognosis
 - The boundary between genes and environment is not distinct (e.g. epigenetics)
-

7. The Heritability of ASD




- Different types of knowledge may be gleaned:
 - Genetic studies offer more direct path to elaborating molecular and cellular mechanisms, pharmacological intervention, and ability to study epigenetics;
 - environmental studies identify potentially modifiable risks.
 - The two together will ultimately answer the key questions about risk, trajectory and intervention
-

8. Why has it been so hard to find ASD genes?



- Highly genetically and phenotypically heterogeneous disorder
 - Until very recently, we have had a very limited ability to search through the genome
 - Not a single gene; not a 1:1 relationship between genetic risk and outcome.
-




10. Genetic Variation



- Any two individuals are ~ 99% identical
 - We are interested in the ~1% difference
 - Variations are the basis of the genetic risk
 - “Gene discovery” is “variation discovery”
 - Sequence: SNP (single nucleotide polymorphism) or SNV (single nucleotide variant)
 - Structural -- gains and losses of genetic material at submicroscopic resolution: CNV (Copy Number Variant)
 - Common and rare: boundary is ~1% of the population carrying the variation.
-


11. Microarrays



12. Sequencing



Costs per 1,000,000 base pairs DNA



Cost of sequencing all the coding regions of the genome:
~\$1500.00\$/per individual

Costs of sequencing the entire human genome
~\$4,000.00/per individual


13. What Does the Recent Data Show?



- Rare mutations contribute to ASD risk
 - Contribution of common variants is an open question, but other conditions, including schizophrenia, suggest that larger studies will confirm alleles of small effect (Review: Devlin et al, *Brain Res* 2011)
 - Rare mutations in “syndromic” and “idiopathic” ASD point to synaptic function; unlikely to be the only path, (Reviews: Toro et al, *Trends Genet* 2010; Bill and Geschwind, *Curr Opin Genet Devel*, 2009)
-



Piccolo






15. Recent Data: Copy Number Variation



- Large *de novo* CNVs are present in about 6-10% of ASD and carry large, clearly identifiable, highly reproducible risks
- Particular risks for large multigenic *de novo* CNVs (OR= 5.6; Sanders et al *Neuron* 2011)
- Inherited CNVs also carry risk, but it is harder to discern than for regions that also have *de novo* events
- These *de novo* CNVs are large risk factors for ASD and are not strongly related to IQ
- Girls appear to be protected: CNVs need to be larger and more gene rich than in boys, do not show any relation to IQ (Sanders et al *Neuron* 2011; Levy et al *Neuron* 2011)
- Even strong genetic risk factors do not appear to be specific to ASD (Review: Sebat et al, *Trends Genet* 2009)

16. Recent Data: Copy Number Variation



872 pairs

17. Recent Data: Copy Number Variation




- 16p11.2 deletions* and duplications*: clear and convincing replication. 1% of cases of “idiopathic” ASD (Weiss et al *NEJM* 2008; Kumar et al *Hum Mol Genet* 2008; Marshall et al. *Am J Hum Genet* 2008)
- 7q11.23 duplications strongly associated with ASD
- 7q11.23 is the Williams syndrome region, characterized by a highly affiliative personality
- 4 regions had recurrent de novo and rare transmitted CNVs (found only in cases)
 - 1q21.1*, 15q13.3*, 16p13.2 *, 16q23.3 (*CDH13*)



- *De novo* events corresponding to previously identified regions
 - 22q11.2*, 15q11-13*, Neurexin 1*, PTCHD1-DDX53
 - ~250-300 de novo CNV regions in the human genome carrying risk for ASD (Sanders et al *Neuron* 2011; Levy et al *Neuron* 2011)
 - So many individually rare variations do not mean that each affected individual will need a different treatment
-

19. Recent Data



20. What Next?



- Replication may not be as “exciting”, but reflects a critical milestone
 - Common variants can provide important information on risk, course and gene x environment interactions:
 - False dichotomy #2: common vs. rare mutations
 - Rare CNVs: Still much more to discover
 - Move to biology predicated on clear, reproducible and *large* risks: biochemistry, iPSCs, model systems, systems biology
 - Next generation sequencing: the total dataset
 - Genetic epidemiological studies to investigate gene x environment interactions; we are now able to think about this *vis a vis* both common and rare variation
-

21. What Next?



- Prospective cohort studies of individuals with the same high risk variants: really one risk multiple disorders?
 - Tackle multiple variations contributing simultaneously
 - Combine neuroimaging with genetic studies, based on clearly defined risk
 - Clarify the role of epigenetics through genetic discoveries
 - We can identify genetic risks in a significant minority of cases, but this is only the first step
 - Move from a deeper understanding of mechanism to treatment and prevention
-

22. What Next?



- We *finally* have the tools in hand to address the major obstacles:
 - heterogeneity (sample sharing, advocacy groups; NIH)
 - limited ability to “look” at the genome (arrays and next generation sequencing)
 - and the lack of 1:1 relationship of genotype to phenotype (1 and 2 above)
 - The pace is slower than anyone would like, but the progress is substantial and rapidly accelerating
-